MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$15.09 USD
-0.26 (-1.69%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $15.08 -0.01 (-0.07%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INKT 15.09 -0.26(-1.69%)
Will INKT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INKT
New Strong Sell Stocks for August 22nd
INKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INKT
Is INKT poised for gains? 20 Day Moving Average Support shows up after sliding 1.69%
Crossed Above 20 Day Moving Average appears for INKT after 7.79% move
Is INKT showing downside potential? 20 Day Moving Average Resistance shows up after sliding 2.4%
MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases
MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases